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Abstract
Background: This study aimed to explore the responses to the interleukin-6 (IL-6)/soluble interleukin-6 receptor
(sIL-6R) complex in peritumoral endothelial cells (PECs) and tumor endothelial cells (TECs), as well as determine the
signaling pathways in the angiogenesis of hepatocellular carcinoma (HCC).
Methods: The expression of IL-6, IL-6R, gp130, CD68, HIF-1α, and microvessel density (MVD) were assessed with
an orthotopic xenograft model in nude mice. ECs were incubated under hypoxic conditions to detect IL-6 and
gp130. The proliferation of PECs and TECs in the presence of IL-6 and sIL-6R, as well as the expression of gp130,
JAK2/STAT3, PI3K/AKT in endothelial cells were measured.
Results: Peritumoral IL-6, IL-6R, gp130, CD68, and HIF-1α expression, as well as MVD, gradually increased during
tumor growth. Hypoxia could directly induce IL-6 expression, but not gp130 in PECs. The co-culture of IL-6/sIL-6R
induced much higher PEC proliferation and gp130 expression, as well as the elevated phosphorylation of JAK2
and STAT3, however not the phosphorylation of PI3K and AKT.
Conclusions: PECs exhibited higher proliferation in response to IL-6/sIL-6R co-treatment compared with TECs in HCC
via the up-regulation of gp130 /JAK2/STAT3. PEC and its associated peritumoral angiogenesis microenvironment may
be a potential novel target for anti-angiogenic treatment.
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Background
Angiogenesis is a fundamental event in the process of
hepatocellular carcinoma (HCC) growth and metastatic
dissemination [1, 2]. The current understanding of
angiogenesis is mostly focused on tumor angiogenesis.
However, reports from our group and others have im-
plied that more pro-angiogenic factors are present in
pertitumoral liver tissue compared with those in tumor
tissue [3–7]. Furthermore, peritumoral angiogenesis can
predict tumor metastasis and patient prognosis [6, 8, 9].
Therefore, the activation and proliferation of endothelial
cells (ECs) to develop new vessels from pre-existing ones
are vital for the process of angiogenesis. ECs may be
strictly classified into tumor ECs (TECs) and peritumoral
ECs (PECs). TECs and PECs should be specifically studied
in terms of their different biological functions during
angiogenesis and response to pro-angiogenic factors.
TECs and PECs are known to possess different charac-
teristics in terms of their morphology [10], pathophysi-
ology [11], cytogenetics [12], epigenetics [13], and gene
expression [14]. Our previous study showed that TECs
demonstrate increased apoptotic resistance, motility, and
other pro-angiogenic properties, with the increased ability
to adhere to tumor cells and survive in the tumor environ-
ment, compared with PECs [15]. These results suggested
that the differences between PECs and TECs may account
for their different levels of efficiency in therapy, such as in-
creased resistance to adriamycin, 5-fluorouracil, and soraf-
enib in TECs [15]. Therefore, an improved understanding
of the different signaling events that mediate the response
to pro-angiogenic factors between TECs and PECs will* Correspondence: junshen_xh@163.comDepartment of General Surgery, Xinhua Hospital, School of Medicine,
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lead to the development of improved anti-angiogenesis
therapies for HCC.
Interleukin-6 (IL-6) plays a role in primary tumor pro-
gression [16]. The genetic signature derived from non-
tumor liver tissue may reflect the promoting effects of
IL-6 on the development of metachronous tumors that
are independent from the primary resected HCC [17, 18].
Tumor-derived IL-6 is known to promote EC proliferation
and new blood vessel generation that support the high
metabolic demands of tumor cells. The cell signaling path-
way of IL-6 for EC proliferation has been previously stud-
ied, and the formation of the IL-6/IL-6R/gp130 complex
on the EC surface can induce PI3K/AKT or JAK2/STAT3
activation and cell proliferation [19, 20]. ECs lack IL-6R,
and soluble IL-6R eventually plays an important role in
EC proliferation via the trans-signaling pathway; conse-
quently, signaling occurs after the formation of the IL-6/
sIL-6R/gp130 complex on the EC surface [21, 22]. How-
ever, the aforementioned functional studies were mostly
conducted with established cell lines, such as the human
umbilical vein ECs (HUVECs). The use of HUVECs
causes an obvious disadvantage because these cells are de-
rived from large vessels that lack the typical characteristics
of TECs and PECs. Therefore, the characterization of dif-
ferent responses to IL-6/sIL-6R treatment in TECs and
PECs, as well as their respective signaling pathways, may
reveal EC characterization.
A prevalent paradigm in tumor biology is that TECs
may have a much higher proliferation rate when respond-
ing to pro-angiogenic factors, such as IL-6 or sIL-6R. This
paradigm was challenged by the present study. Our results
showed that PECs had much higher levels of cell prolifera-
tion when co-cultured with IL-6/sIL-6R by automatically
up-regulating their cell surface gp130 levels in vitro and
activating JAK2/STAT3 signaling pathway, which had
no effect on the PI3K/AKT signaling pathways. Our re-
sults also demonstrated that IL-6 secretion by PECs
was induced by peritumoral hypoxia, and the increased
IL-6 levels contributed to the much higher proliferation
of the cells.
Methods
Cell lines and culture conditions
PECs and TECs were obtained from surgical HCC speci-
mens and their surrounding normal liver tissue immedi-
ately after removal from patients, as previously described
in our laboratory [15]. ECs were isolated from the cell sus-
pension by anti-CD105 antibodies coupled to magnetic
beads (Miltenyi Biotech, Germany) and magnetic cell sort-
ing with the MACS system (Miltenyi Biotech,, Germany)
[15]. Cells were grown in complete EBM-2 medium sup-
plemented with 10 % fetal bovine serum, 100 U/mL peni-
cillin, and 100 μg/mL streptomycin. ECs between passages
1 and 6 were used in the subsequent experiments within
six months after resuscitation. The study was approved by
the Xinhua Hospital Research Ethics Committee. In-
formed consent was obtained according to the commit-
tee's regulations.
Tumor xenograft
Six-week-old male BALB/c nu/nu nude mice, weighing
approximately 20 g each (Shanghai Institute of Materia
Medica, Chinese Academy of Sciences, Shanghai,
China), were housed in laminar flow cabinets under
specific pathogen-free conditions. Orthotopic implant-
ation of human HCC cell line HCCLM3 in BALB/c
mice was performed as previously described [23–25].
The mice were cared and handled in accordance with
the National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals. The experimental
protocol was approved by the Shanghai Medical Experi-
mental Animal Care Committee. To study EC prolifera-
tion and angiogenesis-related genes in peritumoral tissue
during tumor growth, 18 mice of the HCC tumor model
was established by orthotopic implantation of a histologi-
cally intact tumor tissue derived from HCCLM3 cell line,
and 6 mice were killed at the end of the 2, 5 and 7wk after
tumor injection respectively.
Tissue microarray and immunohistochemistry (IHC)
We constructed a tumor microarray (Shanghai Biochip
Co., Ltd, Shanghai, China) as described in our previous
study [9]. After reviewing HE-stained slides for the loca-
tion of tumor tissue and tissue adjacent to tumor (TAT)
with the distance of 2 cm away from tumor, we con-
structed TMA slides (collaborated with Shanghai Bio-
chip Company, Ltd, Shanghai, China). Two cores were
taken from each formalin-fixed, paraffin-embedded HCC
and TAT sample, respectively, by using punch cores that
measured 1.0 mm in greatest dimension from the non-
necrotic area of tumor foci and TAT. The following pri-
mary antibodies were used: mouse monoclonal anti-IL-6,
anti-IL-6R, and anti-gp130 antibodies (Abcam, Cambridge,
MA, USA), rabbit polyclonal anti-CD31 and anti-HIF-1α
antibodies (Abcam, Cambridge, MA, USA), and mouse
monoclonal anti-CD68 antibody (1:100; Zymed Laborator-
ies, San Francisco, CA, USA). The density of positively
stained cells was measured as specified in our previous
study [9]. The integrated optical density was deter-
mined using Image-Pro Plus v6.2 software (Media Cy-
bernetics, Inc., Bethesda, MD, USA) with the same
setting for all the slides. To quantify the mean micro-
vessel density (MVD), five fields at 100× magnification
in the CD31-stained “hotspot” were photographed. The
MVD was quantified as the ratio of the CD31-positive
area to the total area.
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Reverse transcription PCR (RT-PCR) analysis
The mRNA levels of IL-6, IL-6R, and gp130 in the peritu-
moral liver tissue, as well as those of IL-6 and gp130 in
the PECs and TECs, were detected as follows. Total RNA
was extracted following the manufacturer’s protocol (Invi-
trogen). Real-time RT-PCR analysis for quantification was
performed using an SYBR Premix Ex Taq™ (perfect real
time; TaKaRa). The relative mRNA expression was nor-
malized to that of β-actin. The relative amount of tissue
mRNA was standardized by the amount of β-actin mRNA,
and expressed as − △CT =CT(factor) −CT(β-actin). The
ratio of the number of mRNA copies to the number of β-
actin mRNA copies was then calculated as 2–△CT × K,
where K is a constant. The primers for RT-PCR are listed
in Additional file 1: Table S1.
Western blot analysis
After 24 and 48 h of incubation with different stimula-
tory agents (IL-6, sIL-6R, IL-6 and sIL-6R), the PECs
and TECs were harvested and lysed or homogenized
for Western blot analysis. The primary antibodies for
the analysis included IL-6, IL-6R, gp130, p-JAK2
(Y1007/1008), JAK2, p-STAT3(Y705), STAT3, p-
PI3K(Y607), PI3K, p-Akt(S473), Akt and GAPDH (Cell
Signaling Technology, Beverly, MA). Specific protein
expression levels were normalized to the GAPDH pro-
tein. All experiments were performed in triplicate and
densitometric analysis was performed for the statis-
tical significance.
Immunocytochemistry
The primary antibodies used were rabbit polyclonal gp130
(1:100; Santa Cruz, CA, USA) and rabbit monoclonal IL-6
(1:200; Abcam, Cambridge, MA, USA) antibodies. The
primary antibody was detected by the secondary anti-
bodies of anti-rabbit IgG-TR (Texas Red; Abcam) and
anti-mouse IgG-FITC (Abcam). Cells were incubated with
the respective primary antibody overnight at 4 °C. Sections
were washed three times in PBS, followed by incubation
with the secondary antibody for 1 h at room temperature.
Samples were analyzed with an inverted fluorescence
microscope (Olympus IX51) equipped with an Olympus
Qcolor 3 digital camera (Olympus).
Cell proliferation assay
The cultured PECs or TECs were plated in triplicate
into 96-well plates containing EBM-2 medium for 10 h.
To detect the cellular response to IL-6 (20 ng/ml) and
sIL-6R (100 ng/ml) treatment (R&D Systems, Minneap-
olis, MN, USA), cells were cultured for 24, 48, and 72 h
in medium containing different drugs at the indicated
concentrations. The Cell Counting Kit-8 (CCK-8)
(Dojindo Laboratories, Kumamoto, Japan) was used to
determine cell viability. All experiments were per-
formed in triplicate.
Cell culture and hypoxia
PECs and TECs were incubated in 37 °C under a humidi-
fied atmosphere (5 % CO2) for 24 and 48 h in the presence
or absence of cobalt chloride (CoCl2, 100 μmol/L), which
was used to mimic the effects of hypoxia by its minimal
effect on cell viability Both cell types were then harvested
for detection of IL-6 and gp130 expression by immuno-
cytochemistry and RT-PCR.
Statistical analysis
All statistical analyses were performed with SPSS version
16.0 software. The Spearman rank correlation coefficient
was used to analyze the correlations among parameters.
Quantitative variables were expressed as the mean ±
standard deviation, and analyzed with the t-test. P < 0.05
was considered statistically significant.
Results
Gradually increased levels of IL-6 IL-6R, gp130, CD68, and
MVD in peritumoral liver tissue
Compared with HCC tumor tissue, several EC prolif-
eration and angiogenesis-related genes in peritumoral
tissue were gradually up-regulated during seven weeks
of tumor growth, including IL-6, IL-6R, and gp130,
which was confirmed by RT-PCR (using mouse-
specific primers), IHC staining (Fig. 1a, c) and West-
ern blot (Fig. 1f ). The results showed more than a
twofold change in the expression ratio of seven
weeks/five weeks. Specifically, the expression of IL-6
(3.45-fold), IL-6R (2.35-fold), and gp130 (4.21-fold)
changed. The expression levels of representative mice
after seven weeks of tumor growth were visualized by
IHC (Fig. 1a), and the corresponding expression curve
after seven weeks was shown in Fig. 1c. The Western
blot analysis also revealed the similar trend of IL-6,
IL-6R and gp130 during tumor growth (Fig. 1f ). Peri-
tumoral MVD followed a similar trend after seven
weeks of tumor growth, which was confirmed by IHC
(20.2 % ± 0.9 % vs. 15.6 % ± 2.4 % for seven and five
weeks, respectively; P = 0.021, Fig. 1e). Previous stud-
ies stated that macrophages contribute to sIL-6R se-
cretion [26, 27]. We found that peritumoral CD68(+)
macrophages were also up-regulated on the seventh
week of tumor growth (Fig. 1a); this change was sig-
nificantly associated with peritumoral IL-6R (rr =
0.556, P = 0.001).
The expression pattern of all the factors (IL-6, IL-6R,
gp130, and CD68) was not similar among the tumor
tissues, such that all the factors were gradually up-
regulated until five weeks. Subsequently, all the factors
were down-regulated, and RT-PCR indicated that the
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expression ratios of seven weeks/five weeks of IL-6,
IL-6R, and gp130 in tumor growth decreased by 0.43-
fold, 0.47-fold, and 0.33-fold, respectively. These re-
sults were also confirmed by IHC (Fig. 1b, d) and
Western blotting (Fig. 1f ). Similarly, the MVD was
down-regulated from that after five weeks of tumor
growth (13.5 % ± 1.4 % vs. 28.6 % ± 5.8 % for seven
and five weeks, respectively; P = 0.014; Fig. 1d). These
Fig. 1 a–f levels of IL-6, IL-6R, gp130, CD68(+) macrophages and MVD in peritumoral liver tissue and tumor tissue. Peritumoral HIF-1α, IL-6, IL-6R,
CD68, gp130, and CD31 gradually increased after seven weeks of tumor growth. The samples were then examined by tissue microarray and IHC
(expression levels from representative mice in the seven weeks of tumor growth, as indicated by IHC, are shown in a; the expression curve during
the seven weeks is shown in c). However, the expression patterns of all the six factors were not similar in the tumor tissue because they were
gradually up-regulated until five weeks and then became down-regulated, the expression curves after seven weeks of tumor growth are shown
in b and d. The expression of IL-6, IL-6R, and gp130 in both peritumoral and tumor tissue were also confirmed by Western blot analysis (f). Bar,
50 μm. * P < 0.05; **P < 0.01
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results were much lower than that of peritumoral
MVD (P = 0.004).
Hypoxia induced IL-6 expression in PECs
To further elucidate the peritumoral microenvironment
during the up-regulation of IL-6, we stained peritumoral
tissues with the hypoxia indicator HIF-1α. The peritumoral
expression of IL-6 gradually increased during tumor growth
(Fig. 1a, c). Peritumoral HIF-1α were in accordance with
the peritumoral IL-6 expression (rr = 0.721, P = 0.004). To
determine whether hypoxia can directly up-regulate the ex-
pression of IL-6 in PECs, we treated PECs to hypoxic or
normoxic conditions for 24 and 48 h. The results demon-
strated that IL-6 was significantly up-regulated in PECs
under hypoxic conditions for 48 h, which was confirmed
by immunocytochemistry (Fig. 2a), IHC (Fig. 2b), and RT-
PCR (mean − △CT, −0.01 ± 0.003 vs. –0.17 ± 0.052 for hyp-
oxic and normoxic conditions, P = 0.014, Fig. 2c). However,
we found that hypoxia had no direct effect on PEC prolifer-
ation in vitro for 24 and 48 h (1.17 ± 0.01 vs. 1.16 ± 0.01,
P = 0.714 and 2.23 ± 0.01 vs. 2.25 ± 0.02, P = 0.628 under
hypoxic and normoxic conditions for 24 and 48 h, respect-
ively; cell proliferation was evaluated by the CCK-8 assay).
Hypoxia did not up-regulate gp130 in PECs
PECs were further characterized for the distinct expression
of endothelial surface markers: IL-6R(−) and gp130(+). The
expression levels of endothelial markers were tested at the
Fig. 2 a–d Hypoxia induced IL-6 expression in PECs. Hypoxia could significantly and directly up-regulate the expression of IL-6 after 48 h in PECs,
as indicated by immunocytochemistry (a), IHC (b), and RT-PCR (c). However, hypoxia had no direct effects on gp130 expression in PECs, as indicated
by immunocytochemistry (a) and RT-PCR (c). Bar, 50 μm
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first, third, and fifth passages, and similar results were con-
firmed during cell culture. We investigated the expression
levels of gp130 in PECs under hypoxic conditions. The
levels of gp130 were not affected by hypoxia for 24 and
48 h based on immunocytochemistry (gp130 expression
under hypoxic and normoxic conditions for 48 h was
shown in Fig. 2a) and RT-PCR [mean − △CT: −12.5 ± 0.04
vs. −13.1 ± 0.05 (P = 0.825) and −10.7 ± 0.05 vs. −9.9 ± 0.07
(P = 0.545) under hypoxic and normoxic conditions for 24
and 48 h, respectively, Fig. 2c].
Effect of IL-6 and sIL-6R on the proliferation of PECs and
TECs
We subsequently determined the effects of IL-6 and sIL-
6R on EC proliferation, and found that neither IL-6 nor
sIL-6R alone had an effect on the proliferation of PECs
and TECs (Fig. 3). To determine whether the presence of
both IL-6 and sIL-6R can induce the proliferation of PECs
and TECs, we co-cultured both cell types with IL-6 and
sIL-6R. Interestingly, the proliferation of both PECs and
TECs was much higher when the cells were grown to-
gether with IL-6 and sIL-6R compared with that of cells
grown with either IL-6 or sIL-6R for 48 h and 72 h (espe-
cially predominant for 48 h), and no obvious different was
observed in 24 h. Therefore, cell proliferation increased in
response to the co-culture environment. Further, PECs
showed a much higher rate of proliferation in response to
the co-culture environment than TECs [2.65 ± 0.01 vs.
2.25 ± 0.02 for PECs under the co-cultured and vehicle
conditions for 48 h, respectively (P = 0.0004); 1.50 ± 0.01
vs. 1.37 ± 0.01 for TECs under the co-cultured and vehicle
conditions for 48 h, respectively (P = 0.029)]; cell prolifera-
tion was evaluated by the CCK-8 assay; Fig. 3, Table 1].
Effects of IL-6 or sIL-6R on the expression of gp130 and
JAK2/STAT3, PI3K/AKT in PECs and TECs
IL-6 or sIL-6R alone had no effect on the proliferation of
ECs. Considering the predominant higher proliferation of
ECs when co-culture with both IL-6 and sIL-6R for 48 h,
we examined the effects of IL-6 or sIL-6R on the cell
Fig. 3 a–d Effect of IL-6 and sIL-6R on the proliferation of PECs and TECs. IL-6 or sIL-6R alone had no effect on the proliferation on PECs and
TECs. The co-culture of both IL-6 and sIL-6R could induce PEC and TEC proliferation. PECs showed much higher proliferation in response to
the co-cultured environment for 48 and 72 h as compared with TECs. Representative images of PECs (a) and TECs (b) in different culture conditions
after 48 h. Absorbance of PECs (c) and TECs (d) at 24, 48, and 72 h in different culture conditionss
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signaling pathways in EC proliferation for 48 h, in terms
of the gp130, JAK2/STAT3 and PI3K/AKT expression.
First, we found the administration of IL-6 or sIL-6R alone
could not promote the expression of all the factors (Fig. 4),
however, co-culture with both IL-6 and sIL-6R lead to a
synergistic increase in gp130 expression, and this value
was especially much higher in PECs with respect to the
mRNA (RT-PCR, mean − △CT: −14.9 ± 0.22 vs. −19.5 ±
0.15 for IL-6/sIL-6R vs. control in PECs, P = 0.0005; −16.2
± 0.11 vs. −18.4 ± 0.22 for IL-6/sIL-6R vs. control in TECs,
P = 0.045) and protein levels by Western blot analysis
(Fig. 4). Furthermore, phosphorylation of JAK2 and STAT3
in PECs were significantly increased when co-culture with
both IL-6 and sIL-6R for 48 h, and the phosphorylation of
both factors were not so obvious for 48 h in TECs, while
phosphorylation of PI3K and AKT were not affected in
both cells (Fig. 4).
Discussion
This study reported that PECs demonstrated a much
higher level of cell proliferation under co-culture with IL-
6/sIL-6R by automatically up-regulating their cell surface
gp130 proteins and increased phosphorylation of JAK2
and STAT3. The present study confirmed that hypoxia in-
duced elevated IL-6 levels in PECs, however, no direct ef-
fects on cell proliferation were observed. Animal studies
confirmed that peritumoral MVD was much higher than
tumor MVD when tumors were large. Therefore, PECs
and their associated peritumoral angiogenesis microenvir-
onment are worthy of attention.
The novel finding in this study is that peritumoral angio-
genesis was much higher than tumor angiogenesis when
tumors had increased in size. The peritumoral angiogenesis
microenvironment was much richer in terms of its much
higher levels of hypoxia, IL-6, IL-6R, gp130, and CD68(+)
macrophages. The present study showed that PEC prolifer-
ation relied on the up-regulation of IL-6/sIL-6R and gp130,
which was in accordance with peritumoral hypoxia.
Table 1 The absorbance of ECs under different culture
conditions of IL-6 and/or sIL-6R
Control IL-6 sIL-6R IL-6 + sIL-6R
TECs 24 h 0.92 ± 0.01a 0.93 ± 0.01 0.95 ± 0.01 0.94 ± 0.01
48 h 1.37 ± 0.01 1.40 ± 0.01 1.39 ± 0.01 1.50 ± 0.01*
72 h 1.56 ± 0.01 1.59 ± 0.02 1.57 ± 0.01 1.66 ± 0.01*
PECs 24 h 1.16 ± 0.01 1.15 ± 0.01 1.21 ± 0.01 1.22 ± 0.01
48 h 2.25 ± 0.02 2.28 ± 0.02 2.31 ± 0.01 2.65 ± 0.01***
72 h 2.50 ± 0.01 2.53 ± 0.01 2.51 ± 0.02 2.71 ± 0.01*
acell proliferation was evaluated by CCK-8 assay and results were expressed as
the absorbance of each well which was read at 490 nm with a microplate
reader (Nexcelom, Lawrence, MA). Culture medium (EBM-2 medium) without
cells was used as blank control. All experiments were performed in triplicate
Student t test was conducted between different groups with stimulation of
(IL-6 and /or sIL-6R) and control group
* P < 0.05; *** P < 0.001
Fig. 4 Effect of IL-6 or sIL-6R on the expression of gp130 and JAK2/STAT3, PI3K/AKT in PECs and TECs. Administration of IL-6 or sIL-6R alone
could not promote the expression of gp130, PI3K, and AKT after 24 and 48 h. However, co-culture with both IL-6 and sIL-6R for 48 h could
lead to a synergistic increase in gp130 levels, and the increased phosphorylation of JAK2 and STAT3, which were all notably higher in PECs. By
contrast, no increase was observed in the PI3K and AKT expression of both PECs and TECs. Western blot analysis of the control group, IL-6
group, sIL-6R group, and co-cultured IL-6 and sIL-6R group for 48 h were shown in Fig. 4. * P < 0.05; **P < 0.01
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Previous studies showed that anti-angiogenic factors exert
an inhibitory effect on HCC growth mainly through anti-
tumor angiogenesis [23, 28–31]. However, higher peritu-
moral angiogenesis is more important for intrahepatic
metastasis during the progress of tumor growth. Atten-
tion should be given to peritumoral angiogenesis as the
major therapeutic target.
In the present study, higher peritumoral IL-6 levels
were proven to be derived from PECs. The IL-6 levels
were induced by peritumoral hypoxia and associated
with large tumor sizes. Therefore, we postulated that the
compression effect on peritumoral tissues, as induced by
the primary tumor, could create the peritumoral hypoxia
environment, which contributed to IL-6 expression in
peritumoral tissue and subsequent PEC proliferation.
IL-6 plays several roles in the pathway. Combining the
membrane containing IL-6R and gp130 forms the IL-6/IL-
6R/gp130 complex, which activates the JAK2/STAT3 or
PI3K/AKT pathway and subsequent biological activities
[19, 20], such as EC proliferation. Our present study found
that IL-6 alone was unable to directly stimulate TEC and
PEC proliferation. The lack of IL-6R on the surface of ECs
suggested that IL-6 may exert its effect on ECs by combin-
ing with sIL-6R, and then it combines with the EC surface
gp130 and ultimately activates the JAK2/STAT3 or PI3K/
AKT pathway via the trans-signaling pathway. Our in vitro
study confirmed that sIL-6R was an important factor of
the vascular EC proliferation signaling pathway, which was
consistent with other studies [21, 22], however, we also
found that only the combination of IL-6 and sIL-6R
could induce EC proliferation via JAK2/STAT3 signal-
ing pathways however not the PI3K/AKT pathway. Pre-
vious studies have proven that macrophages or neutral
granulocytes can contribute to sIL-6R secretion [26, 27,
32]. We found that the increased extensive distribution
of macrophages was also associated with IL-6R. How-
ever, whether or not IL-6R is derived from macro-
phages requires further investigation.
In addition, we found that PECs had a stronger re-
sponse to co-culture with IL-6 and sIL-6R compared
with TECs. This result may be caused by the different
cell signaling pathways between PECs and TECs during
EC proliferation. gp130 is an important cell surface fac-
tor that is crucial for cell proliferation. Interestingly, we
found that gp130 could be directly up-regulated in ECs
after the administration of both IL-6 and sIL-6R. How-
ever, hypoxia had no direct effect on the expression of
surface gp130 on PECs, which was in contrast to previ-
ous studies that stated that gp130 is controlled by HIF-
1α [33, 34], and the controversial may be attributed to
the fact that HIFs may differentially regulate the expres-
sion of the same angiogenic gene in different cell types;
In our present study, the mechanism of gp130 expres-
sion unmodulated in PECs under hypoxia condition may
be due to its distinct cell surface markers: IL-6R(−) and
gp130 (+). In vivo study, only co-administration of both
IL-6 and sIL-6R could lead to a synergistic increase in
gp130 expression, which indicated that the up-regulation
may be associated with effect of both IL-6 and IL-6R,
and the elevated IL-6 on PECs by hypoxia could not
alone up-regulate gp130 expression on PEC cell without
IL-6R, and instead, the elevated peritumoral sIL-6R de-
riving from the macrophages together with elevated
peritumoral IL-6 could lead to the higher expression of
gp130 in peritumoral tissue, which had no direct correl-
ation with peritumoral hypoxia.
The PECs comprise the key members of the peritu-
moral angiogenesis microenvironment. Previous studies
suggested that the differences in the molecular pheno-
type of vascular ECs in normal and diseased tissues
leads to different functions in both cell types [35]. This
phenomenon was confirmed by our studies between
PECs and TECs. The optimized immune magnetic sort-
ing method allowed us to successfully obtain PECs with
a high level of purity. These cells could be successfully
passed in culture and used in the associated angiogen-
esis research studies [15, 36]. In the present study, the
automatic up-regulation of gp130 as well as the in-
creased phosphorylation of JAK2 and STAT3 in re-
sponse to the combination of IL-6 and sIL-6R in PECs
may also explain its more pro-angiogenic properties.
PECs may be more sensitive to the anti-angiogenesis
therapy target at IL-6/sIL-6R or gp130/JAK2/STAT3.
Conclusions
This study demonstrated that PECs and TECs differed
in their mode of angiogenesis. Although both cell types
demonstrated proliferation only under co-stimulation
with IL-6 and sIL-6R, the PECs showed a much higher
proliferation rate, which was related to the automatic
up-regulation of cell surface gp130 in PECs, as well as
the increased phosphorylation of JAK2 and STAT3. In
addition, the PI3K/AKT signaling pathways was not asso-
ciated with the cells. Elevated peritumoral IL-6 expression
in PECs, as well as peritumoral IL-6R expression induced
by peritumoral hypoxia, could promote PEC proliferation
and peritumoral angiogenesis. Furthermore, given the sen-
sitivity of PECs to IL-6/sIL-6R, the PECs are the potential
new targets for anti-angiogenic treatments.
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